I think they should. It would be awesome if they could show they already can create a single natural looking human hair on a human skin. No need to figure out how to do it on scale or efficiently now, just show us a single good looking human hair.
Actual picture of the biodegradable scaffold Stemson is using for hair cloning
- Thread starter werefckd
- Start date
Well they need to:
1. Get some cell material from the patient (blood, skin, etc.)
2. Convert the material into iPS cells
3. (Probably) Expand those iPS cells
4. Convert the iPS cells into neural crest cells
5. Differentiate the neural crest cells into dermal papilla cells
We're talking about probably days to weeks between each step. Complex stuff.
I believe that's why they want in the later future to switch from autologous to allogenic hair cloning. They could do all these steps in bulk instead of for each patient individually (much slower and more expensive).
Yea, and even if you have the money there is going to be waiting lines too
After the 5th step, they will need to load each lolli-up with the exact right proportion of dermal papilla and epithelial cells (and possibly other accessory components as well).
And then transport it to the clinic that is going to do the implants.
And then a skilled surgeon will individually implant each lolli-up filled with cells in your scalp.
Well the CEO of Stemson Geoff Hamilton said, back in the middle of 2020,1.5 years to start clinical trials. But I think it will take more.sounds like 10 years from nowaway
No need to, he gave us a pretty comprehensive YT interview a short time ago.
Btw, Terskikh paints a much more accurate picture of the current stage they really are at than Geoff and their press releases/PR pieces.
- Reaction score
- 292
what happen after the DP cell and epithelial cell are placed into skin with scaffold? do he have growth factors like tsuji did?
Watch the Dr. Pinto video, she explains that. Don't know about the growth factors.
In that regard aren't they already ahead of where Tsuji was? I could be mistaken but I believe I read somewhere that Tsuji has yet to even successfully clone hair/cells and only implanted existing follicles on mice, whereas Stemson seems to have at least gotten to that step.
NorwoodGuardian
Established Member
- Reaction score
- 184
When did Stemson start his hairloss research? These years I only heard about Tsuji and Tisusse but never heard a company called Stemson, maybe I focused too much on Tsuji. But then I realised that Stemson is not worse than Tsuji! Glad to have Stemson and Tisusse, Tsuji is dead.
- Reaction score
- 292
if you notice in the video, she said "only some hair showed growth and cycling" which mean not all of the scaffold will produce hair. you can see in picture one the nude mice grew all those thing wispy hairs and only some successful ones. Antonella pinto is so sexy and have sexy voice
- Reaction score
- 984
"Here we find the main player in the current hair multiplication research to be Stemson Therapeutics in the North American market. The company publicised the outline of its technology this past summer at the Annual Meeting of the International Society for Stem Cell Research founded just two years ago.
Then it was Stemson hoping to start those clinical trials in humans in early 2021 where according to the indications it was given at that meeting. If this turns out to be overly optimistic, we will have to wait and see. " http://humanhairgrowth.com/good-new...ning-news-in-2020-when-is-it-available-part-2
can anybody confirm that information?
Then it was Stemson hoping to start those clinical trials in humans in early 2021 where according to the indications it was given at that meeting. If this turns out to be overly optimistic, we will have to wait and see. " http://humanhairgrowth.com/good-new...ning-news-in-2020-when-is-it-available-part-2
can anybody confirm that information?
Nope. He said 3-4 years at lease before it can be deployed to the clinic. If you watch the whole interview and consider other statements by Dr. K and Geoff (the company CEO) he by that probably meant commercial launch.
The CEO of the company said in the middle of 2020 that he was expecting to start human trials in 16 months. So the BEST case scenario, human trials will begin in the beginning of 2022. My opinion is that is everything goes right they will be able to start human trials by the end of 2022.
The next step for Stemson if the start of pre clinical studies with animals that are not mice. That's where we should be focusing at now as far as news goes. If they start pre clinical studies in 2021 it will be probably the best news of the year.
No chance. In another statement to the media this year he said 16 months again. I think it's a blank statement of him. He always says "16 months" whenever asked, no matter when - it's just a rolling prediction that doesn't mean much. The truth is that they haven't got a clue until they move from mice and start pre clinical studies.
They would probably have announced it if it was the case. During 2020 they had a lot of business related news to share but nothing new came related to the research itself.
When comparing their latest papers published they were a little ahead since the hair they created was "half" cloned (dermal papilla cells used were cloned but epithelial cells not). But both companies supposedly evolved their research past those publications so it's hard to know.
What we know is that in theory, the way Stemson is approaching the hair cloning problem is better than Tuji's, because with it they don't have the cells amplification problem that supposedly Tsuji had.
But I will only consider Stemson "officially" ahead of Tsuji when they start pre clinical studies and get positive data from that. Until then they are in reality still too early, like Tsuji was, IMO.
But of course Stemson didn't run out of money like Organ/Tsuji di (yet), in fact they appear to be well funded and they are growing their team which is a good thing. But the jury is still out.
Last edited:
The first paper by Dr. Terskikh on this subject was published on Jan/15. https://pubmed.ncbi.nlm.nih.gov/25607935/ - but he was researching it years before that.
To the people just noticing Stemson -- they are currently our only real hope to deliver hair cloning in the near future. They are planning to advance their research in UK. There they can release their treatment before getting regulatory approval (clinical trials):
It is a conceivable notion that Stemson may be interested in utilizing the Specials regulation as a way to test and fine-tune its hair regeneration therapy before conducting a full-fledged clinical trial in the UK. This announcement comes on the heels of a $7.5M investment that Stemson received from Allergan Aesthetics and Fortunis Capital, which is an investment firm based in the UK. Geoff Hamilton, CEO of Stemson, shared this statement regarding the potentials of expanding into Great Britain: “The UK is on our short list with its world class scientific talent and infrastructure, and I know Fortunis Capital certainly believe we will find full support for this level of scientific innovation in the UK.” Interesting stuff going on here.
Stemson Planning To Move Research Into The UK (11/12/20)
An interesting development has been announced by Stemson Therapeutics, a company based in Southern California focused on developing hair regeneration therapies. In a news release shared on November 10, 2020, Stemson announced that they are targeting the UK as a location to further their R&D and potentially conduct their first human trial in. Perhaps the most interesting facet of this news is the fact that we are familiar with the UK having a unique regulatory allowance referred to as “Specials.” In the case of Specials, physicians are able to prescribe and administer treatments which have not gone through a full clinical trial process to patients if said treatments are determined to be reasonably safe and are filling a need where other treatment options do not yet exist. Multipled dermal papilla cell injections may be an example of this. The one catch is that companies who develop the up-and-coming treatments are not allowed to market their treatment to patients and the decision to attempt the treatment must solely come from the physician and then the patient.It is a conceivable notion that Stemson may be interested in utilizing the Specials regulation as a way to test and fine-tune its hair regeneration therapy before conducting a full-fledged clinical trial in the UK. This announcement comes on the heels of a $7.5M investment that Stemson received from Allergan Aesthetics and Fortunis Capital, which is an investment firm based in the UK. Geoff Hamilton, CEO of Stemson, shared this statement regarding the potentials of expanding into Great Britain: “The UK is on our short list with its world class scientific talent and infrastructure, and I know Fortunis Capital certainly believe we will find full support for this level of scientific innovation in the UK.” Interesting stuff going on here.
They are seriously considering the UK move, but nothing is confirmed yet. Fingers crossed they go that path.
- Reaction score
- 984
THE PROBLEM
Regenerative Science has been a product of fiction, unobtainable in the real world, and as a society the only option we had to manage and mitigate illness and loss was within our own bodies – until now.THE SOLUTION
Ranked amongst the top Biotech innovations the world has ever seen, our team of scientists have spent the last 12 years working towards a major breakthrough in Stem Cell regenerative science that has global application in our daily lives. In July 2019 our team achieved this breakthrough, and is now working towards a practical application. Our certainty – the world will be changed at every level when this science is released.DELIVERING REAL POSITIVE CHANGE
- Huge numbers within our global community will have significantly enhanced self-confidence and mental and physical well-being.
- This Stem Cell technology has a large number of other applications, already identified by the team, for future investments.
- The IP is fully protected, and the rights to commercialise the regeneration of hair follicles via Stem Cell science is completely owned by the Investee.
- There is an opportunity to develop the world’s first Stem Cell manufacturing line in the UK.
- Time to human clinical trials within the next 18 months.
- Leading US pharma partner deeply involved.